Veru (STU:FMW) Institutional Ownership : 7.20% (As of Jun. 09, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Veru's institutional ownership is 7.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Veru's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Veru's Float Percentage Of Total Shares Outstanding is 89.38%.

Veru Institutional Ownership Historical Data

The historical data trend for Veru's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Institutional Ownership Chart

Veru Historical Data

The historical data trend for Veru can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	9.24	8.82	6.67	6.76	6.31	6.27	6.27	6.84	7.20	7.20

Veru Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines